Device Trial Radar · NCT03270982
Comprehensive Segmental Revision System
Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Apr 2016
Primary completion
Dec 2035
Study completion Dec 2035
Sponsor
- Lead sponsor
- Zimmer BiometPublic (ZBH)
- Sponsor type
- Industry
- First posted
- Sep 1, 2017
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical Data evaluation to document the performance and clinical outcomes of the Comprehensive Segmental Revision System.
Conditions
- Degenerative Disease
- Oncology
- Revision Surgery
- Trauma
- Rheumatoid Arthritis
Interventions
Comprehensive SRS ReplacementDevice
This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Implant survivorship assessed according to the implant revisionsTime frame: 10 years
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
Department of Orthopedic Surgery, Rigshospitalet University of Copenhagen
Copenhagen, Denmark
Royal Liverpool University Hospital
Liverpool, United Kingdom
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.